Stockreport

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing

Fortress Biotech, Inc.  (FBIO) 
Last fortress biotech, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: fortressbiotech.com
PDF Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Th [Read more]